Background: It remains unclear whether concomitant use of omeprazole attenuates platelet function in Asian patients with acute coronary syndromes (ACS) receiving clopidogrel according to cytochrome P450 (CYP) 2C19 phenotype. Methods: Stent implantation was performed in 177 patients with ACS receiving aspirin 100mg/day and clopidogrel 75mg/day. The platelet reactivity index (PRI) was determined on admission and average 18 days of after stenting with VASP assay. Results: On the basis of CYP2C19 genotype, 46 patients (26%) were classified as extensive metabolizers (EM), 103 (58%) as intermediate metabolizers(IM), and 28 (16%) as poor metabolizers (PM). There were no significant differences in baseline characteristics among 3 phenotypes. At baseline, PRI was similar in patients with PPIs and those without among 3 phenotypes. Among EM, patients with PPIs had higher PRI at 18 days (45Ϯ16 vs 38Ϯ13%; Pϭ0.05) and the smaller PRI variation (-45vs-59%, p Ͻ0.01) compared with those without. In contrast, there were no significant differences in PRI (55Ϯ18 vs 53Ϯ15%) and the mean PRI variation (-35%vs-36%) in patients with PPIs and those without among IM. Similar trends were found in PRI (69Ϯ10 vs 73Ϯ8%) and the mean PRI variation (-18vs-15%) among PM (pϭNS, respectively).
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Pharmacodynamic Effect of Adjunctive Cilostazol vs. High-dos Clopidogrel in Acute Coronary Syndrome Patients According to the CYP2C19 Genotype (ACCEL-GENOTYPE) study
Young-Hoon Jeong 1 , Yongwhi Park 2 , Jin-Sin Koh 2 , Seok-Jae Hwang 2 , Choong Hwan Kwak 2 , Jin-Yong Hwang 2 , Udaya Tantry 1 , Paul Gurbel 1 1 Sinai Center for Thrombosis Research, Baltimore, MD, 2 Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do Background: Cilostazol use in ACS patients reduces the risks of ischemic events and restenosis in East Asians. Compared with Caucasians, East Asians have higher frequency of CYP2C19 loss-of-function allele (*2 and *3). We compared the pharmacodynamic effect of adjunctive cilostazol vs. high-dose clopidogrel in PCI-treated East Asians with ACS according to CYP2C19 genotype. Methods: ACS patients were assigned to either clopidogrel 150 mg/d (DOUBLE; nϭ139) or cilostazol 100 mg twice a day ϩ clopidogrel 75 mg/d (TRIPLE; nϭ136) on top of aspirin. Platelet aggregation (PA) was measured at baseline and follow-up (Ն 30-day) with conventional aggregometery and adjusted with known clinical covariates. Primary endpoint was the level of 20 M ADP-induced PA at follow-up. HPR was defined as 20 M ADP-induced PA Ͼ 59%. Results: During standard-dose clopidogrel, platelet measurements did not differ according to individual CYP2C19 genotype between the groups (Fig. A) . PA levels and the risk of HPR increased across CYP2C19 genotype (p Յ 0.174). At follow-up, TRIPLE vs. DOUBLE showed significantly lower level of PAs irrespective of CYP2C19 genotype (Fig. B ). DOUBLE showed 27.3% of HPR risk, which was increased across CYP2C19 genotype (adjusted p ϭ 0.042), whereas TRIPLE effect was not significantly influenced with CYP2C19 genotype (adjusted p ϭ 0.289). Similar trend was observed for collagen-induced PA.
Conclusions:
In PCI-treated East Asians presented with ACS, adjunctive cilostazol to dual antiplatelet therapy exhibited favorable platelet measurements compared with high-dose clopidogrel irrespective of CYP2C19 genotype. Background: Current guidelines recommend that pts undergoing coronary stenting receive dual-antiplatelet therapy to prevent acute stent thrombosis. There is limited data on platelet inhibition in pts presenting with cardiac arrest who require both acute coronary stenting and therapeutic hypothermia (TH). We sought to determine the extent of platelet inhibition in pts requiring TH who were treated with clopidogrel. Methods: We prospectively recruited pts who presented with a cardiac arrest who required TH and acute coronary stenting. The loading dose of clopidogrel was 600mg followed by a maintenance dose of 75mg daily administered via a nasogastric tube. Platelet function was tested at baseline, and at 4, 8, 24, 48, 72, 96 and 120 hrs from the loading dose of clopidogrel. Platelet activity was analyzed with the VerifyNow point-ofcare rapid platelet function analyzer. Primary endpoint was the extent of platelet inhibition as a function of time. Results: We evaluated 8 consecutive patients who received coronary stents and subsequently required TH. The results of the platelet testing are depicted in the figure TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM www.jacc.tctabstracts2012.com Background: Stent thrombosis is a feared complication following stent implantation. The multi-factorial causes include low anti-platelet response (LR) to the routinely used drug, clopidogrel. Newer anti-platelet drugs such as prasugrel and ticagrelor have higher potency with less inter-individual variability in platelet response, however with an increased bleeding risk. We sought to evaluate the safety and anti-platelet effect of double-dose clopidogrel as compared with normal-dose prasugrel in patients with clopidogrel LR undergoing non-urgent PCI. Methods: ЉTAILORЉ is a randomized, open-label, single-centre trial. All patients pre-treated with clopidogrel and undergoing PCI were screened for clopidogrel LR by whole-blood aggregometry, using the Multiplate analyzer® (Dynabyte, Germany) where low response to clopidogrel was defined as Multiplate ADP Ͼ 70 units. Patients demonstrating LR were randomized to either 150 mg clopidogrel or 10 mg prasugrel (5 mg for patients Ͼ 75 years or Ͻ 60 kg). Results: Of 990 patients screened, 246 (24.9%) exhibited LR to clopidogrel. Of these, 100 (40.5%) were randomized to one of the two regimens (nϭ50 in each group); the remaining served as controls. Main reasons for non-inclusion were previous stroke, ongoing anti-coagulant treatment or inability to return for follow up visit. At 1 month, anti-platelet response was normalized in a total of 67 patients: 37 (75.5%) in the prasugrel vs 30 (61.2%) in the clopidogrel group (pϭ0.123, unadjusted) . Overall, prasugrel resulted in a greater decrease in Multiplate ADP values (30.1 Ϯ21.2 U for prasugrel vs 21.2 Ϯ22.4 U for clopidogrel (pϭ0.046)). There were no bleeding episodes, myocardial infarction, stroke or death during the follow-up. Conclusions: Tailoring of anti-platelet treatment in patients with clopidogrel LR undergoing non-urgent PCI translates into improved platelet inhibition with both normaldose prasugrel and double-dose clopidogrel, however with a more pronounced effect with prasugrel. Antwerpen, Belgium, 6 Medisch Centrum Alkmaar, Alkmaar, Alkmaar, 7 Flinders Medical Center, Bedford Park, South Australia, 8 Lady Davis Carmel medical Center, Haifa, Haifa, 9 Henry Ford Heart and Vascular Institute, Detroit, MI, 10 AstraZeneca Research and Development, Molndal, Molndal, 11 Duke Clinical Research Institute, Durham, NC, 12 Professor Cardiology, Uppsala, Sweden, 13 Uppsala Clinical Research Center, Uppsala, Sweden Background: Patients with prior coronary artery bypass graft surgery (CABG) who present with an acute coronary syndrome have high risk for recurrent events. Whether more intensive antiplatelet therapy with ticagrelor might be beneficial compared to clopidogrel is unknown. In this substudy of the PLATO trial we studied the effects of randomized treatment dependent on history of CABG. Methods: Patients participating in PLATO were classified according to whether they had prior CABG. The trial's primary and secondary end points were compared using Cox proportional hazards regression. Results: Of the 18,613 study patients, 1,133 (6.5%) had prior CABG, of whom 353 (31%) underwent percutaneous coronary intervention in a saphenous vein graft and 190 (17%) in a native coronary artery. Prior CABG patients had more high risk characteristics at study entry, experienced more clinical events during follow-up, but had less major bleeding (Table) . The primary endpoint (composite of cardiovascular death, myocardial infarction, and stroke) was reduced to a similar extent by ticagrelor among patients with [19.6% vs. 21.4%; hazard ratio (HR), 0.90 (0.69, 1.17)] and without [9.2% vs. 11.0%; HR, 0.84 (0.76, 0.93), Pinteractionϭ0.66] prior CABG. Major bleeding was similar with ticagrelor vs. clopidogrel among patients with [8.1% vs. 8.7%; HR, 0.93 (0.61, 1.43)] and without [11.8% vs. 11.4%; HR, 1.04 (0.95, 1.14), Pinteractionϭ0.61] prior CABG. Table: Outcomes in patients with and without prior coronary artery bypass graft surgery (CABG). TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM www.jacc.tctabstracts2012.com JACC Vol 60/17/Suppl B | October 22-26, 2012 | TCT Abstracts/POSTER/Antithrombin and Antiplatelet Agents B215
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